2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5973 Treosulfan- versus clofarabine-based reduced-intensity conditioning for AML and MDS: Results of an early-terminated randomized phase II trial

Phuong T Vo, MD, Jason P. Cooper, MD, PhD2, Kevin Ng, MS3, Masumi Ueda Oshima, MD, MA4, Boglarka Gyurkocza, MD5, Filippo Milano I, MD, PhD6, Ted Gooley, PhD7, Joachim Deeg, MD8, Brenda M Sandmaier, MD9
1 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
2 University of Washington School of Medicine, Seattle, Washington, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States
4 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
5 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
6 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
7 Fred Hutch Cancer Center, Seattle, Washington, United States
8 Fred Hutch Cancer Center, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States

Reduced-intensity conditioning (RIC) regimens have expanded access to allogeneic hematopoietic cell transplantation (HCT) for older adults and comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). However, relapse, toxicity, and non-relapse mortality (NRM) remain important concerns, and the optimal RIC platform balancing disease control and toxicity is not well established. Treosulfan- and clofarabine-based regimens have antileukemic and immunosuppressive activity, but prospective comparative data are limited.

We conducted a single-center, randomized phase II trial (NCT04994808) comparing treosulfan/fludarabine/low-dose total-body irradiation (TBI) versus clofarabine/low-dose TBI conditioning in adults aged 18–75 years with AML or MDS with excess blasts undergoing HLA-matched related or unrelated donor HCT. Patients were required to have <5% marrow blasts at HCT. Patients received treosulfan 10 g/m²/day IV days −6 to −4, fludarabine 30 mg/m²/day IV on days −6 to −2, and 2–3 Gy TBI (TREO), or clofarabine 40 mg/m²/day IV on days −6 to −2 and 2–3 Gy TBI (CLOF). Per FDA input, reduced doses of treosulfan and clofarabine were used compared with the prior phase II trials that formed the basis for the two study arms. Grafts were G-CSF–mobilized PBSC. GVHD prophylaxis was cyclosporine/mycophenolate mofetil, with sirolimus added for unrelated donors. Randomization was stratified by IPSS-R risk for MDS and measurable residual disease (MRD) status for AML. The primary endpoint was 6-month relapse-free survival (RFS). Secondary endpoints included 1-year overall survival (OS), relapse, NRM, acute GVHD, and post-HCT hospitalization by day +100. The study was designed to randomize 80 patients 1:1 using a pick-the-winner design, where the arm with better 6-month RFS would potentially move forward. The trial closed early after sponsor funding was discontinued due to slow accrual; thus, analyses are descriptive. RFS and OS were estimated by Kaplan-Meier methods, and relapse and NRM by cumulative incidence methods.

Twenty-three patients were randomized, 11 to TREO and 12 to CLOF. Median age was 67 (range, 58.8–70.8) years and 66.5 (range, 63.3–75.3) years; median HCT-CI was 1 (range, 1–7) and 1 (range, 1–3), respectively. In the TREO arm, 7 patients had AML and 4 had MDS; in the CLOF arm, 9 had AML and 3 had MDS. All patients achieved neutrophil engraftment by day +28, with median times of 13 (range, 11–23) and 14 (range, 10–18) days, respectively. Platelet engraftment occurred in 11/11 TREO and 11/12 CLOF patients; one CLOF patient died of disseminated fungal infection on day +26 before platelet engraftment. Median times to platelet engraftment were 16 (range, 11–19) and 17 (range, 14–20) days, respectively.

Nine of 11 TREO and 11 of 12 CLOF patients survived without relapse to 6 months, with estimated 6-month RFS of 81.8% (95% CI, 44.7–95.1) and 91.7% (95% CI, 53.9–98.8), respectively. Estimated 1-year RFS, OS, relapse, and NRM in the TREO vs. CLOF arm were:  71.7% (95% CI, 35.0–89.9) vs. 81.5% (95% CI, 43.5–95.1); 67.5% (95% CI, 29.1–88.2) vs. 91.7% (95% CI, 53.9–98.8); 18.2% (95% CI, 2.5–46.0) vs. 8.3% (95% CI, 0.45–38.0) and 9.1% (95% CI, 0.43–38.0) vs. 8.3% (95% CI, 0.42–32.0), respectively.

Grade II–IV acute GVHD occurred in 0 TREO and 4 CLOF patients (33.3%); grade III–IV acute GVHD occurred in 0 and 1 patient, respectively. Late grade II–IV acute GVHD occurred in 2 patients in each arm, and late grade III–IV acute GVHD occurred in 1 TREO patient (grade IV) after GVHD prophylaxis discontinuation for MRD. One-year cumulative incidence estimates of NIH chronic GVHD were 36.4% and 41.7%; estimates for moderate-to-severe chronic GVHD were 27.3% and 16.7%, in the TREO and CLOF arms, respectively. Median total hospitalization from day 0 through day +100 was 13 days (range, 1–26) in the TREO arm and 21 days (range, 0–40) in the CLOF arm.

In this early-terminated randomized phase II trial, both treosulfan- and clofarabine-based RIC regimens were feasible and supported prompt engraftment with low NRM in older adults with AML/MDS. Although limited by small numbers, 6-month RFS, 1-year RFS, and 1-year OS were encouraging. The CLOF arm showed numerically higher 1-year OS and lower relapse. These hypothesis-generating results support further evaluation of RIC regimen selection in larger randomized studies.

Funding: Treosulfan was provided by medac GmbH; financial support was provided by Medexus Pharma, Inc.

Phuong T Vo, MD: Medexus Pharmaceuticals, Inc. - Research Funding